FAVL elevation in human tumors disrupts Fanconi anemia pathway signaling and promotes genomic instability and tumor growth

Journal of Clinical Investigation

Volumn 120, Issue 5, 2010, Pages 1524-1534

  Zhang, Jun ^a   Zhao, Deping ^a,c   Park, Hwan Ki ^a   Wang, Hong ^a,d   Dyer, Roy B ^a   Liu, Wanguo ^b   Klee, George G ^a   McNiven, Mark A ^a   Tindall, Donald J ^a   Molina, Julian R ^a   Fei, Peiwen ^a  

^a MAYO CLINIC   (United States)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

^d SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FANCONI ANEMIA GROUP L PROTEIN; FANCONI ANEMIA PROTEIN; FAVL PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; CONCENTRATION (PARAMETERS); CYTOPLASM; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; FANCONI ANEMIA; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL; TUMOR GROWTH; TUMOR PROMOTION; WESTERN BLOTTING;

ANIMALS; BASE SEQUENCE; CARCINOMA; CHROMOSOME ABERRATIONS; DISEASE PROGRESSION; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP L PROTEIN; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; HUMANS; MALE; MICE; MICE, NUDE; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; NEOPLASM TRANSPLANTATION; SEQUENCE HOMOLOGY, NUCLEIC ACID; SIGNAL TRANSDUCTION;

EID: 77951826151     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI40908     Document Type: Article

References (41)

1. Swift M. Fanconi's anaemia in the genetics of neoplasia. Nature. 1971;230(5293):370-373.
2. Bagby GC, Alter BP. Fanconi anemia. Semin Hematol. 2006;43(3):147-156.
3. Alter BP, Greene MH, Velazquez I, Rosenberg PS. Cancer in Fanconi anemia. Blood. 2003;101(5):2072.
4. Howlett NG, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002;297(5581):606-609.
5. Litman R, et al. BACH1 is critical for homologous recombination and appears to be the Fanconi anemia gene product FANCJ. Cancer Cell. 2005;8(3):255-265. (Pubitemid 41317595)
6. Levitus M, et al. The DNA helicase BRIP1 is defective in Fanconi anemia complementation group J. Nat Genet. 2005;37(9):934-935. (Pubitemid 43086148)
7. D'Andrea AD, Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer. 2003;3(1):23-34.
8. Fei P, Yin J, Wang W. New advances in the DNA damage response network of Fanconi anemia and BRCA proteins. FAAP95 replaces BRCA2 as the true FANCB protein. Cell Cycle. 2005;4(1):80-86. (Pubitemid 41038932)
9. Wang W. Emergence of a DNA-damage response network consisting of Fanconi aneamia and BRCA proteins. Nat Rev Genet. 2007;8(10):735-748. (Pubitemid 47429206)
10. Rahman N, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007;39(2):165-167. (Pubitemid 46184346)
11. Niedzwiedz W, Patel KJ. "Dub"bing a tumor suppressor pathway. Cancer Cell. 2005;7(2):114-115.
12. Bagby GC Jr. Genetic basis of Fanconi anemia. Curr Opin Hematol. 2003;10(1):68-76.
13. Taniguchi T, et al. Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. Cell. 2002;109(4):459-472. (Pubitemid 34564473)
14. Grompe M, van de Vrugt H. The Fanconi family adds a fraternal twin. Dev Cell. 2007;12(5):661-662. (Pubitemid 46671150)
15. Smogorzewska A, et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell. 2007;129(2):289-301. (Pubitemid 46584733)
16. Ciccia A, et al. Identification of FAAP24, a Fanconi anemia core complex protein that interacts with FANCM. Mol Cell. 2007;25(3):331-343. (Pubitemid 46206138)
17. Ling C, et al. FAAP100 is essential for activation of the Fanconi anemia-associated DNA damage response pathway. EMBO J. 2007;26(8):2104-2114. (Pubitemid 46625801)
18. Meetei AR, et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet. 2003;35(2):165-170.
19. Gurtan AM, Stuckert P, D'Andrea AD. The WD40 repeats of FANCL are required for Fanconi anemia core complex assembly. J Biol Chem. 2006;281(16):10896-10905. (Pubitemid 43855513)
20. Reid S, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet. 2007;39(2):142-143. (Pubitemid 46184345)
21. Cantor SB, Andreassen PR. Assessing the link between BACH1 and BRCA1 in the FA pathway. Cell Cycle. 2006;5(2):164-167.
22. Meetei AR, et al. A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. Nat Genet. 2005;37(9):958-963.
23. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10(8):789-799. (Pubitemid 39070849)
24. Zhang J, Wang X, Lin CJ, Couch FJ, Fei P. Altered Expression of FANCL confers mitomycin C sensitivity in Calu-6 lung cancer cells. Cancer Biol Ther. 2006;5(12):1632-1636. (Pubitemid 46256640)
25. Taniguchi T, D'Andrea AD. Molecular pathogenesis of Fanconi anemia: recent progress. Blood. 2006;107(11):4223-4233. (Pubitemid 43801344)
26. Kennedy RD, D'Andrea AD. The Fanconi Anemia/BRCA pathway: new faces in the crowd. Genes Dev. 2005;19(24):2925-2940.
27. Masuda N, et al. Establishment of tumor cell lines as an independent prognostic factor for survival time in patients with small-cell lung cancer. J Natl Cancer Inst. 1991;83(23):1743-1748.
28. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643-646. (Pubitemid 37310920)
29. Pal T, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104(12):2807-2816. (Pubitemid 41798292)
30. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000;408(6810):307-310.
31. Bartel F, Taubert H, Harris LC. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell. 2002;2(1):9-15. (Pubitemid 41043984)
32. Christofk HR, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature. 2008;452(7184):230- 233.
33. Taniguchi T, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med. 2003;9(5):568-574. (Pubitemid 36597103)
34. D'Andrea AD. The Fanconi road to cancer. Genes Dev. 2003;17(16):1933- 1936.
35. Franchitto A, Pichierri P. Werner syndrome protein and the MRE11 complex are involved in a common pathway of replication fork recovery. Cell Cycle. 2004;3(10):1331-1339. (Pubitemid 40268617)
36. Lee JW, Harrigan J, Opresko PL, Bohr VA. Pathways and functions of the Werner syndrome protein. Mech Ageing Dev. 2005;126(1):79-86. (Pubitemid 40018480)
37. Monnat RJ Jr. Werner syndrome: molecular genetics and mechanistic hypotheses. Exp Gerontol. 1992;27(4):447-453.
38. Kudlow BA, Kennedy BK, Monnat RJ Jr. Werner and Hutchinson-Gilford progeria syndromes: mechanistic basis of human progeroid diseases. Nat Rev Mol Cell Biol. 2007;8(5):394-404.
39. Fei P, et al. Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell. 2004;6(6):597-609. (Pubitemid 40017703)
40. Fei P, Bernhard EJ, El-Deiry WS. Tissue-specific induction of p53 targets in vivo. Cancer Res. 2002;62(24):7316-7327. (Pubitemid 36025255)
41. Yoshioka N, Wang L, Kishimoto K, Tsuji T, Hu GF. A therapeutic target for prostate cancer based on angiogenin-stimulated angiogenesis and cancer cell proliferation. Proc Natl Acad Sci U S A. 2006;103(39):14519-14524. (Pubitemid 44484782)